Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pan Afr Med J ; 37: 78, 2020.
Article in English | MEDLINE | ID: mdl-33244341

ABSTRACT

INTRODUCTION: the most recently discovered severe acute respiratory syndrome Coronavirus 2 (SARS-COV-2) that causes COVID-19, subjected the entire world in turmoil health-wise and economically. With higher burden of malaria in Nigeria and other sub-Saharan African countries coupled with fragile healthcare system and delivery, these may pose a threat in the diagnosis and management of COVID-19 patients co-infected with malaria. Free radicals have been implicated in the progression and pathogenesis of malaria and COVID-19 through Fenton's reaction and cytokine storm respectively. METHODS: the current research comprises of seventy-four (74) participants; 20 apparently healthy controls and 54 COVID-19 patients (34 among which were co-infected with malaria). Serum levels of 8-iso PGF2α and Alphatocopherol were determined among the study participants using ELISA technique and colorimetric assay, respectively. RESULTS: results revealed statistically significant elevation of 8-iso PGF2α in COVID-19 patients co-infected with malaria compared to COVID-19 patients only, and this may be due to increase production of free radicals. Furthermore, a significant decrease of Alphatocopherol was observed in COVID-19 co-infected with malaria compared to COVID-19 patients due to increase utilization of antioxidants in counterbalancing the negative effect of free radicals generated. CONCLUSION: conclusively, SARS-COV-2 patients co-infected with malaria might be predisposed to oxidative stress and low Alphatocopherol. The increase in oxidative stress is proportional to malaria parasite density and inversely related to Alphatocopherol levels. This implies that oxidative stress is notably higher and such patients may have a severer form of the COVID-19. Increased 8-iso-PGF2α in co-infection and decreased alphatocopherol levels can reflect the severity and adverse outcomes compared to COVID-19 naïve because of their tremendous involvement in the pathogenesis and progression of diseases.


Subject(s)
COVID-19/blood , Coinfection/blood , Dinoprost/analogs & derivatives , Malaria/blood , SARS-CoV-2 , alpha-Tocopherol/blood , Biomarkers/blood , COVID-19 Testing/methods , Case-Control Studies , Coinfection/diagnosis , Colorimetry/methods , Cross-Sectional Studies , Dinoprost/blood , Female , Humans , Malaria/diagnosis , Malaria/parasitology , Male , Nigeria , Oxidative Stress , Pandemics , Reverse Transcriptase Polymerase Chain Reaction
2.
J Obes ; 2019: 4929131, 2019.
Article in English | MEDLINE | ID: mdl-31354987

ABSTRACT

This review article stresses the effective role of dietary fish fillet docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) on overweight as a risk factor of cardiovascular disease (CVD) via platelet phospholipid modification. Several reports have demonstrated that saturated fat in overweight evokes systemic inflammation and more importantly predisposes it to cardiovascular disorder. Prospective studies have shown that saturated fat is directly proportional to the level of arachidonic acids (AA), precursor of thromboxane in the platelet phospholipid membrane as omega-6 fatty acid in overweight and obese people. Some literature has demonstrated that omega-3 fatty acid from fish fillet ameliorates inflammation, reduces proinflammatory cytokine, inhibits signaling pathway, and regulates the physical composition of inflammatory leukocytes and free radicals (ROS). Yellow stripe scad (YSS) is a local Malaysian fish that has been shown to contain a comparable level of EPA/DHA content as observed in salmon. This review article will focus on the dietary role of fish fillet that will balance the omega-6 fatty acid/omega-3 fatty acid ratio in platelet phospholipid from YSS to manage and prevent healthy overweight/obesity-related risk factor of CVD and to avoid the risk orthodox drug treatment.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Eicosapentaenoic Acid/analogs & derivatives , Fish Oils/pharmacology , Fishes/classification , Hypercholesterolemia/diet therapy , Inflammation/diet therapy , Phospholipids/physiology , Adult , Animals , Anti-Inflammatory Agents/pharmacology , Docosahexaenoic Acids/pharmacology , Docosahexaenoic Acids/therapeutic use , Eicosapentaenoic Acid/pharmacology , Eicosapentaenoic Acid/therapeutic use , Fatty Acids, Omega-3/pharmacology , Fatty Acids, Omega-3/therapeutic use , Fatty Acids, Omega-6/pharmacology , Fatty Acids, Omega-6/therapeutic use , Female , Humans , Hypercholesterolemia/epidemiology , Hypercholesterolemia/prevention & control , Inflammation/epidemiology , Inflammation/prevention & control , Malaysia/epidemiology , Male , Prospective Studies , Species Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...